Literature DB >> 21636552

BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

Eric H Raabe1, Kah Suan Lim, Julia M Kim, Alan Meeker, Xing-Gang Mao, Guido Nikkhah, Jarek Maciaczyk, Ulf Kahlert, Deepali Jain, Eli Bar, Kenneth J Cohen, Charles G Eberhart.   

Abstract

PURPOSE: BRAF is frequently activated by gene fusion or point mutation in pilocytic astrocytoma, the most common pediatric brain tumor. We investigated the functional effect of constitutive BRAF activation in normal human neural stem and progenitor cells to determine its role in tumor induction in the brain. EXPERIMENTAL
DESIGN: The constitutively active BRAF(V600E) allele was introduced into human neurospheres, and its effects on MAPK (mitogen-activated protein kinase) signaling, proliferation, soft agarose colony formation, stem cell phenotype, and induction of cellular senescence were assayed. Immunohistochemistry was used to examine p16(INK4a) levels in pilocytic astrocytoma.
RESULTS: BRAF(V600E) expression initially strongly promoted colony formation but did not lead to significantly increased proliferation. BRAF(V600E)-expressing cells subsequently stopped proliferating and induced markers of oncogene-induced senescence including acidic β-galactosidase, PAI-1, and p16(INK4a) whereas controls did not. Onset of senescence was associated with decreased expression of neural stem cell markers including SOX2. Primary pilocytic astrocytoma cultures also showed induction of acidic β-galactosidase activity. Immunohistochemical examination of 66 pilocytic astrocytomas revealed p16(INK4a) immunoreactivity in the majority of cases, but patients with tumors negative for p16(INK4a) had significantly shorter overall survival.
CONCLUSIONS: BRAF activation in human neural stem and progenitor cells initially promotes clonogenic growth in soft agarose, suggesting partial cellular transformation, but oncogene-induced senescence subsequently limits proliferation. Induction of senescence by BRAF may help explain the low-grade pathobiology of pilocytic astrocytoma, whereas worse clinical outcomes associated with tumors lacking p16(INK4a) expression could reflect failure to induce senescence or an escape from oncogene-induced senescence. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636552      PMCID: PMC4086658          DOI: 10.1158/1078-0432.CCR-10-3349

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

Review 2.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

3.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Authors:  Eli E Bar; Alex Lin; Vasiliki Mahairaki; William Matsui; Charles G Eberhart
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

4.  Lentiviral-mediated gene transfer into haematopoietic stem cells.

Authors:  N B Woods; H Mikkola; E Nilsson; K Olsson; D Trono; S Karlsson
Journal:  J Intern Med       Date:  2001-04       Impact factor: 8.989

5.  A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702).

Authors:  Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker
Journal:  Neuro Oncol       Date:  2010-09-22       Impact factor: 12.300

6.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis.

Authors:  Alan K Meeker; Jessica L Hicks; Elizabeth A Platz; Gerrun E March; Christina J Bennett; Michael J Delannoy; Angelo M De Marzo
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

7.  Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.

Authors:  Anja E Eisenhardt; Heike Olbrich; Michael Röring; Wibke Janzarik; Ton Nu Van Anh; Huriye Cin; Marc Remke; Hendrik Witt; Andrey Korshunov; Stefan M Pfister; Heymut Omran; Tilman Brummer
Journal:  Int J Cancer       Date:  2011-07-25       Impact factor: 7.396

8.  PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.

Authors:  Erika F Rodriguez; Bernd W Scheithauer; Caterina Giannini; Amanda Rynearson; Ling Cen; Bridget Hoesley; Heather Gilmer-Flynn; Jann N Sarkaria; Sarah Jenkins; Jin Long; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2010-11-28       Impact factor: 17.088

9.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Authors:  Joshua D Schiffman; J Graeme Hodgson; Scott R VandenBerg; Patrick Flaherty; Mei-Yin C Polley; Mamie Yu; Paul G Fisher; David H Rowitch; James M Ford; Mitchel S Berger; Hanlee Ji; David H Gutmann; C David James
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  The transcription factor Sox2 is required for osteoblast self-renewal.

Authors:  U Basu-Roy; D Ambrosetti; R Favaro; S K Nicolis; A Mansukhani; C Basilico
Journal:  Cell Death Differ       Date:  2010-05-21       Impact factor: 15.828

View more
  88 in total

1.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

Review 2.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

3.  Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.

Authors:  Marianne Hütt-Cabezas; Matthias A Karajannis; David Zagzag; Smit Shah; Iren Horkayne-Szakaly; Elisabeth J Rushing; J Douglas Cameron; Deepali Jain; Charles G Eberhart; Eric H Raabe; Fausto J Rodriguez
Journal:  Neuro Oncol       Date:  2013-11-06       Impact factor: 12.300

4.  An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis).

Authors:  J Douglas Cameron; Fausto J Rodriguez; Elisabeth Rushing; Iren Horkayne-Szakaly; Charles Eberhart
Journal:  Trans Am Ophthalmol Soc       Date:  2014

5.  Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.

Authors:  Rachael A Vaubel; Alissa A Caron; Seiji Yamada; Paul A Decker; Jeanette E Eckel Passow; Fausto J Rodriguez; Amulya A Nageswara Rao; Daniel Lachance; Ian Parney; Robert Jenkins; Caterina Giannini
Journal:  Brain Pathol       Date:  2017-04-02       Impact factor: 6.508

6.  Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.

Authors:  Ying Ding; Cong Wang; Xuejie Li; Yangyang Jiang; Ping Mei; Wenbin Huang; Guoxin Song; Jinsong Wang; Guoqiang Ping; Ran Hu; Chen Miao; Xiao He; Gang Chen; Hai Li; Yan Zhu; Zhihong Zhang
Journal:  Diagn Pathol       Date:  2018-08-16       Impact factor: 2.644

Review 7.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

Review 8.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

9.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

10.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.